SCOPE 2021

COVID-19 elevates appreciation, use of RBQM: CluePoints

By Jenni Spinner

- Last updated on GMT

(metamorworks/iStock via Getty Images Plus)
(metamorworks/iStock via Getty Images Plus)

Related tags CluePoints Risk-based monitoring Clinical trials software risk assessment

A leader from the risk-based quality management solutions provider will discuss the growing interest in the technology, during this year’s SCOPE event.

Steve Young, chief scientific officer of CluePoints, will be outlining the benefits of risk-based quality management (RBQM) during several SCOPE Summit presentations this year (see the list below). Outsourcing-Pharma (OSP) discussed with Young how use of the practice has increased in the clinical research realm, as well as how the COVID-19 pandemic has helped accelerate understanding and adoption.

OSP: Could you please share a ‘nutshell’ description of RBQM and why it’s highly useful in the clinical research realm?

SY: RBQM is an approach to managing and ensuring quality in clinical research, that encourages study teams to pro-actively assess operational risk and focus their attention on what matters most to quality and patient safety.  This is leading to much higher quality outcomes in research, along with lower development costs and even shorter timelines! 

OSP: Please share your perspective on how industry attitudes toward and adoption of RBQM practices and principles had been evolving in the months/years leading up to COVID-19’s arrival?

SY: The principles of RBQM and RBM - along with QBD - were introduced a decade or so ago and have been gaining steadily increasing attention and interest across the industry since then.  But most of the attention was educational in nature, and as is typical in our cautious industry, the actual rate of adoption was relatively slow prior to the onset of the Covid pandemic. 

However, we did start to see an inflection point in greater adoption in the years following the ICH GCP revision in 2016 that incorporated RBQM principles.

OSP: Then, COVID-19 hit. How might operations with RBQM principles in place be weathering the pandemic, early on and since, as compared to companies that hadn’t yet adopted?

Steve Young, chief scientific officer, CluePoints

SY: RBQM has proven to be an essential component of success for organizations during the pandemic, especially since it encourages more reliance on centralized and remote methods of monitoring study quality and less reliance on in-person site monitoring which has been severely restricted in the past year. 

OSP: Please share any ways that the pandemic, shutdown and other impacts have underscored RBQM’s usefulness.

SY: In addition to enabling effective quality oversight without the need to visit sites regularly, many organizations leveraged the RBQM risk assessment process to conduct COVID-specific risk assessments that facilitated a clear, effective plan of action to address the challenges faced during the pandemic.

OSP: I understand you’ll be sharing case studies and metrics during your presentation—do you think you could please give us a sneak peek or overview, to share with OSP readers?

SY: We have been compiling an ever-increasing number of central monitoring case studies that are compelling in illustrating the power and value of effective central monitoring.  A couple of the newer use cases we will show illustrate how central monitoring statistical testing was able to retrospectively identify a site known to have significant misconduct and un-reliable data - and would have enabled the study team to identify the issue many months before they actually did.

Young is scheduled to present during the following SCOPE Summit sessions:

  • RBQM/CM Implementation: Lessons from Pfizer’s COVID Vaccine Trial, Tuesday, March 2, 10: 15 am EST
  • How Did We Do? A Review of RBQM’s Impact During COVID-19, Tuesday, March 2, 11:15 am EST
  • Panel—Advancing RBQM: Lessons from the Trenches, Tuesday, March 2, 11:45 am EST
  • Roundtable--Advancing RBQM: Tools, Strategies and Lessons Learned from COVID-19, Wednesday, March 3, 10:30 am EST

For more information about the presentation or other SCOPE Summit sessions, visit​.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more